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Late-onset Pompe disease (LOPD) is characterized by progres-
sive muscle weakness, respiratory muscle dysfunction, and mi-
nor cardiac involvement. Although in LOPD, as in other neuro-
muscular diseases, controlled low impact sub-maximal aerobic 
exercise and functional ability exercise can improve general 
functioning and quality of life, as well as respiratory rehabili-
tation, the bulk of evidence on that is weak and guidelines are 
lacking. To date, there is no specific focus on rehabilitation issues 
in clinical recommendations for the care of patients with Pompe 
disease, and standard practice predominantly follows general 
recommendation guidelines for neuromuscular diseases. The 
Italian Association of Myology, the Italian Association of Pul-
monologists, the Italian Society of Neurorehabilitation, and the 
Italian Society of Physical Medicine and Rehabilitation, have 
endorsed a project to formulate recommendations on practical, 
technical, and, whenever possible, disease-specific guidance on 
rehabilitation procedures in LOPD, with specific reference to 
the Italian scenario. In this first paper, we review available evi-
dence on the role of rehabilitation in LOPD patients, particu-
larly addressing the unmet needs in the management of motor 
and respiratory function for these patients.
Key words: endurance and resistance training, late-onset Pompe 
disease, motor function, rehabilitation, respiratory function
Introduction 
Glycogen storage disease type II, also known as 
Pompe disease, is an autosomal-recessive lysosomal 
storage disorder caused by the deficiency of the lyso-
somal acid α-glucosidase, which results in the accu-
mulation of glycogen deposits inside lysosomes within 
the muscular tissue. Pompe disease manifests clinically 
across a broad spectrum based on age of onset, progres-
sion rate, genetic mutation(s), and disease distribution, 
and is classified as early- (infantile, classic) or late-onset 
(non-classic) (1, 2). 
Late-onset Pompe disease (LOPD) may present at 
any age after the second year of life and is character-
ized by progressive weakness in lower limbs and trunk, 
with only minor cardiac involvement (3, 4). Respiratory 
muscle impairment, the primary cause of morbidity and 
mortality in LOPD patients, is also common and involves 
both inspiratory and expiratory skeletal muscles  (1). To 
this end, and ahead of the current available enzyme re-
placement therapy, rehabilitation might be proposed as 
an effective intervention in improving physical function-
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ing of these patients, however supporting evidence and 
guidelines to support this are lacking (5).
To date, there are no specific guidelines on rehabilita-
tion issues in clinical recommendations for the care of pa-
tients with Pompe disease, and standard practice predomi-
nately follows more general recommendations or, where 
available, guidelines for neuromuscular disease (NMD) (1). 
This lack of treatment guidelines has led to variable and of-
ten limited standards of interventional protocols in clinical 
practice. Moreover, the low prevalence of Pompe disease 
has hindered the development of a national or international 
consensus on the appropriate management of musculoskel-
etal and respiratory impairment in affected patients (1).
The Italian Association of Myology (AIM), the Ital-
ian Association of Hospital Pulmonologists (AIPO), the 
Italian Society of Neurorehabilitation (SIRN), and the 
Italian Society of Physical Medicine and Rehabilitation 
(SIMFER), have endorsed a project to formulate recom-
mendations on practical, technical, and, whenever pos-
sible, disease-specific guidance on rehabilitation pro-
cedures in LOPD, with specific reference to the Italian 
scenario. In this first, narrative paper, we review available 
evidence on the role of rehabilitation in the management 
of LOPD, and define the bases for standardized protocols 
for the assessment and rehabilitation of musculoskeletal 
and respiratory impairments in patients with LOPD.
Methods
A multidisciplinary collaboration of 10 clinicians, 
members of the AIM, AIPO, SIRN, and SIMFER, was es-
tablished to review current evidence in the field of reha-
bilitation in Pompe disease. This open forum agreed that 
two working groups, one on musculoskeletal rehabilitation 
and a second on pulmonary rehabilitation, should be devel-
oped to evaluate available studies and try to standardize pa-
tients’ assessment and exercise plan. To date, evidence as 
to whether rehabilitation is effective in LOPD seems poor 
and contradictory. Therefore, the authors proposed a litera-
ture review based on a search of the EMBASE, CINALH, 
PubMed, PsychINFO, and Scopus databases, using the fol-
lowing keywords: LOPD and guidelines, rehabilitation and 
LOPD, training and LOPD, physical activity and LOPD, 
exercise and LOPD. English language papers published 
between 2000 and 2017 were considered. Papers were se-
lected for inclusion on the basis of their relevance to the 
topic, according to Authors’ judgment.
The level of the evidence of selected studies was de-
fined according to the Scottish Intercollegiate Guidelines 
Network (SIGN). In addition, the Grades of Recommen-
dation, Assessment, Development and Evaluation Work-
ing Group (GRADE) method was used to evaluate the 
quality of evidence with respect to each relevant outcome.
The results of the literature research and the out-
comes of the SIGN and GRADE evaluation are summa-
rized in Tables 1 and 2.
Rehabilitation of motor function in 
LOPD: state of the art
Enzyme replacement therapy (ERT) with recombi-
nant human acid α-glucosidase (Myozyme/Lumizyme) 
was approved in 2006 for the treatment of Pompe disease 
and positive effects of ERT on skeletal muscle strength, 
Table 1. Level of evidence according to the Scottish 
Intercollegiate Guidelines Network (SIGN) for studies in-
vestigating the role of rehabilitation of motor and respira-
tory functions in patients with late-onset Pompe disease.
Studies (Author, date, reference) Level of evidence
Borg 1970 (18) 4
Bach et al. 1996 (48) 2+
Bach 1999 (33) 4
Wasserman et al. 1999 (19) 4
Baydur et al. 2001 (49) 2+
Mellies et al. 2001 (50) 2+
Ragette et al. 2002 (51) 2+
Shneerson et al. 2002 (41) 3
Hill et al. 2004 (40) 4
Slonim et al. 2007 (12) 2-
Mellies et al. 2009 (38) 3
Van der Beek et al. 2009 (34) 2+
Vitacca et al. 2009 (39) 4
van den Berg et al. 2010 (27) 2+
van der Ploeg et al. 2010 (11) 1+
Vitacca et al. 2011 (35) 4
Angelini et al. 2012 (6) 2-
de Vries et al. 2012 (7) 2+
Favejee et al. 2012 (5) 3
van der Ploeg et al. 2012 (46) 1+
Ambrosino et al. 2013 (37) 3
Gungor et al. 2013 (8) 2+
Toscano et al. 2013 (10) 1-
Vianello et al. 2013 (47) 2+
Vitacca et al. 2013 (36) 3
Hundsberger et al. 2014 (45) 2-
Bertoldo et al. 2015 (28) 2-
Crescimanno et al. 2015 (20) 2-
Favejee et al. 2015 (17) 2+
Jevnikar et al. 2015 (43) 2-
Schoser et al. 2015 (31) 4
van den Berg et al. 2015 (13) 2+
Aslan et al. 2016 (42) 2-
Jones et al. 2016 (44) 2-
Schoser et al. 2017 (9) 1-
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walking distance, respiratory function and survival have 
been demonstrated in adult patients with LOPD (6-11). 
Importantly, additional treatments, such as physiotherapy 
or exercise training, may also benefit patients’ fitness and 
physical functioning, however, evidence of such ben-
eficial outcomes is limited (12, 13). Indeed, the need for 
guidance and standardization in the use of physiotherapy 
in clinical practice was highlighted in a Dutch survey of 
88 patients with Pompe disease and 31 physiotherapists, 
which demonstrated a lack of uniformity in the type of 
physical therapy training programs applied  (5). It has 
also been debated as to whether exercise is beneficial or 
harmful for patients with myopathic disorders (14-16). To 
date, only a few studies have investigated the benefits of 
exercise training in adult patients with Pompe disease. An 
uncontrolled, prospective study demonstrated that adher-
ence to a high-protein/low-carbohydrate diet and exercise 
therapy slowed the progressive deterioration of muscle 
function in LOPD patients (12), and a combination of aer-
obic, resistance and core stability exercises were shown 
to be feasible and safe (13) and to improve pain, fatigue 
and functioning (17) in 23 adult patients with Pompe dis-
ease who were receiving ERT and were not dependent on 
ventilators and/or walking devices.
Adherence to a combination of nutrition and exercise 
therapy (mean 4.5 ± 2.5 years, range 2-10 years) in 34 
Table 2. Appropriateness of recommendations according to the GRADE method for outcomes addressed in clinical guide-
lines for the rehabilitation management of motor and respiratory impairments in patients with late-onset Pompe disease.
Clinical Guidelines 
(Author, date, reference)
Level of evidence 
for rehabilitation 
management
GRADE-like recommendations based on level of evidence 
Kishnani et al. 2006 (3) 3 • Submaximal, functional, and aerobic exercise may improve 
muscle function
• Gentle daily stretching, orthotic intervention, splinting, 
seating systems and standing supports may prevent or 
minimize contracture and deformity
Barba-Romero et al. 2012 
(29)
3 • Aerobic exercise may improve motor function
Cupler et al. 2012 (26) 3 • Submaximal aerobic exercise, incorporating functional 
activities may increase muscle strength 
• Daily stretching, orthotic devices, appropriate seating 
position in the wheelchair, and standing supports may 
prevent or slow the development of muscle contractures 
and deformities
Boentert et al. 2016 (1) 3 • Chest physiotherapy and MAC may be sufficient only for 
patients with mild expiratory muscle weakness
• MAC techniques should be implemented by trained 
physiotherapists or respiratory therapists
• Air stacking combined with MAC is recommended if cough 
assistance is indicated and upper airways are patent in 
cooperative patients
• I/E devices are indicated if MAC/air stacking are not 
feasible or ineffective
• HFCWO is indicated if MAC/air stacking are either not 
feasible or ineffective and I/E cannot be tolerated
Llerena Junior et al. 2016 
(30)
2- • Aerobic and progressive resistance exercise training, 
incorporated into daily functional activities, with or without 
ERT, may improve muscle strength and functioning
• Orthotic devices and posture correction while the patient is 
in the wheelchair and support for when the patient stands 
may prevent joint contractures 
Tarnopolsky et al. 2016 (32) 2+ • Tailored endurance exercise and progressive resistance 
training, with or without ERT, may improve aerobic capacity 
and normalize muscle strength, motor function, and lean 
mass
Abbreviations: ERT, enzyme replacement therapy; GRADE, Grades of Recommendation, Assessment, Development and Evaluation 
Working Group; HFCWO, high frequency chest wall oscillation; I/E, Insufflation/Exsufflation; MAC, manually-assisted cough.
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patients (aged 25-66 years), ambulatory except for one 
patient, slowed deterioration of muscle function and 
improved the natural course of LOPD (12). Progressive 
worsening of muscle function was significantly slower in 
26 patients who were compliant with the treatment regi-
men whereas progressive impairment of muscle function 
was reported in 8 noncompliant patients (mean difference 
between pre- and post-therapy Walton score was -0.29 
[95% Confidence Interval (CI) -0.36, -0.19; p  <  0.001] 
for compliant patients, and -0.01 [95% CI -0.36, 0.34; 
p = 0.95] for noncompliant patients) (12).
Endurance, core stability and muscle function im-
proved following a 12-week exercise program, which 
included 36 sessions of standardized aerobic, resistance, 
and core stability exercises, in 23 adult patients (aged > 17 
years) with Pompe disease not dependent on ventilators 
and/or walking devices and receiving ERT for at least 52 
weeks (13). Significant increases in aerobic exercise ca-
pacity and distance walked on the 6 minute walking test 
(6MWT) were demonstrated after training compared with 
before training (maximum workload capacity 122 vs 110 
Watt; peak oxygen uptake 75.9% vs 69.4% of normal; 
6MWT 508 vs 492 meters, respectively; all p  <  0.01). 
Core stability, and muscle function and strength all im-
proved after 12-weeks’ training, with no safety issues re-
ported. Despite being statistically significant, only mod-
est increases were demonstrated in the 6MWT and peak 
workload capacity, however exercise training appears to 
be an effective and safe adjuvant therapy for patients with 
Pompe disease offering added value to treatment with 
ERT alone (13). 
Significant reduction in fatigue (p = 0.001) and pain 
(p = 0.04) were also demonstrated after 12-weeks of ex-
ercise training in the same cohort, but the motor function 
and amount of physical activity did not change signifi-
cantly after training  (17). However, these clinical im-
provements were not correlated with changes in aerobic 
fitness, muscle strength or core stability.
Proposed protocols for the assessment of musculoskeletal 
impairments and rehabilitation – The choice of the 
outcome measure
Evidence supporting the role of musculoskeletal re-
habilitation in patients with LOPD remains scant, main-
ly because it is based on small studies with short follow-
up, conducted in a home-based setting. It is therefore 
difficult to define a standardized protocol for the as-
sessment of motor function for application in the Italian 
scenario. One of the main related issues, that has to be 
considered, is the choice of the best clinic-instrumental 
parameters that are selected as trusted indices to be used 
to evaluate the efficacy of the motor rehabilitative inter-
vention. However, according to the study conducted in 
2015 by Van der Berg and colleagues (13), assessment 
of motor function should include the following outcome 
measurements: 
Endurance: Aerobic exercise capacity was assessed 
using an incremental cycle ergometer with progressive 
increase in exercise intensity until exhaustion (the step-
wise load increment was based on the patient’s functional 
capacities within a range of 5-20 Watts/minute), and con-
tinuous measurement of patients’ heart rates and ventila-
tor parameters using spiroergometry. At exhaustion, the 
Borg scale (18) evaluated exertional symptoms (scale of 
6-20). Measurements of maximum workload capacity 
and peak oxygen uptake capacity were undertaken, and 
the ventilatory threshold was assessed using the ventila-
tory equivalents method  (19). Walking distance on the 
6MWT was evaluated according to the American Tho-
racic Society guidelines (20).
Muscle strength: Although muscle force is consid-
ered a muscle function parameter with limited relevance 
in the evaluation of motor performance in myopathic pa-
tients, there is no doubt that it can represent a useful in-
dex for the construction of motor rehabilitative planning. 
Maximal voluntary contraction, i.e. maximal isometric 
segmental muscle strength, the most accepted meas-
urement in exercise laboratories, was measured using a 
hand-held dynamometry and considered as an index of 
residual muscle function.
Muscle Function: Muscle function assessment com-
prised three timed tests (10 meter running, climbing four 
steps, and rising from supine to standing position), plus 
the Quick Motor Function Test (QMFT) (21). The QMFT 
was designed specifically for and validated in patients 
with Pompe disease, and consists of 16 specific motor 
skills related to daily activities scored on a 5-point scale 
(0 “cannot perform” to 4 “can perform with no effort”); 
a total score, expressed as a percentage of the maximum 
score, is obtained by adding the scores of all items. 
The Rasch-built Pompe-specific Activity (R-PAct) 
scale was validated to specifically quantify the effects of 
Pompe disease on patient’s ability in activities of daily 
life and social participation  (22). This 18-item scale 
demonstrated good discriminative ability and external 
construct validity. Furthermore this assessment tool was 
recently used in a 5-year prospective study, which aimed 
to evaluate the long-term benefit of ERT in 102 adult pa-
tients with Pompe disease (23).
In addition, an assessment of how musculoskel-
etal impairments and rehabilitation affect quality of life 
(QoL) should be undertaken. The Individualized Neu-
romuscular Quality of Life (INQoL) questionnaire (24), 
which consists of 45 questions within 10 sections, was 
designed specifically for NMD and validated for the Ital-
ian population (25).
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The above assessment methods are in line with guide-
lines on the diagnosis and management of patients with 
Pompe disease issued in 2006 by the American College of 
Medical Genetics (ACMG) (3). Musculoskeletal functional 
rehabilitation recommendations from the ACMG include: 
monitoring of cardiorespiratory status; screening for osteo-
penia/osteoporosis; assessment of musculoskeletal impair-
ments, functional deficits, levels of disability and social 
participation; enhancement of muscle function; prevention 
of secondary musculoskeletal impairments; functioning 
optimization with adaptation and assistive technology; 
patient and family education about the natural course of 
Pompe disease and recommendations for intervention (3). 
With regards to the enhancement of muscle function, the 
ACMG recommended that guidelines from other pro-
gressive muscle diseases were to be followed, including: 
sub-maximal, functional and aerobic exercise; avoidance 
of excessive resistive and eccentric exercise; avoidance of 
overwork weakness; and avoidance of disuse atrophy (3).
The proposal for an International Classification 
of Functioning, Disability and Health (ICF)-based ap-
proach (3), although dated now back to 2006, offers an in-
ternationally agreed standard for describing and monitor-
ing functioning, has been endorsed by the World Health 
Organization, and offers a framework for the identifica-
tion of the categories of functional damage, structural 
damage, and limitation of activities of daily living (ADL) 
and of social participation. In Italy, according to the 2013 
national health plan, the ICF has become mandatory to 
allow access to both physiotherapy and aids. It is there-
fore important to publish data based on an ICF checklist 
of items, which recognizes issues specifically related to 
people affected by LOPD. 
The choice of the protocol
In 2012, the American Association of Neuromuscu-
lar & Electrodiagnostic Medicine (AANEM) convened 
a consensus committee to create consensus-based treat-
ment and management recommendations for the treat-
ment of LOPD  (26). Participants clarified that overall 
management of musculoskeletal issues in LOPD patients 
should preserve motor function, prevent secondary com-
plications, maximize benefits of ERT, promote over-
all health, and improve QoL. Importantly, the AANEM 
recognized that there were no established guidelines for 
muscle strengthening or therapeutic exercise for patients 
with LOPD  (26). Although a small number of studies 
have shown that sub-maximal aerobic exercise may in-
crease muscle function and strength, further studies with 
larger sample sizes are needed. Moreover, the AANEM 
recommended the implementation of general precautions 
regarding strengthening exercises, that are followed for 
other degenerative muscle diseases, also be applied to 
LOPD  (26). Furthermore, due to the risk of cardiopul-
monary compromise in LOPD, it was recommended that 
LOPD patients were evaluated by a pulmonologist prior 
to starting an exercise regimen (26).
The frequency and intensity of treatments, from 
a functional and rehabilitative point of view, was also 
addressed by the AANEM. It was recommended that 
therapeutic exercise should start slowly with incremen-
tal increases from mild to moderate intensity in order to 
achieve aerobic levels approximately 60-70% of maximal 
effort; rest periods should be allowed for and the patients 
should aim for a frequency of 3-5 treatment days per 
week (26). A stretching regimen, performed as part of the 
daily routine, should be implemented.
Patients with Pompe disease may be affected by low 
bone mineral density (BMD), putting them at risk of fra-
gility fractures. Indeed, 31 out of 46 patients (67%) had 
BMD Z-score < -1 SD, with the decrease in bone density 
present in both the infantile and late-onset forms of Pom-
pe disease (27). Moreover, low BMD was correlated with 
decreased proximal muscle strength. A recent study also 
identified an increased risk of asymptomatic and atrau-
matic vertebral fractures in patients with LOPD walking 
without assistance and not ventilated, who did not have a 
significant impairment of bone mass (28). The AANEM 
recommended that patients with LOPD undergo annual 
screening with dual-energy X-ray absorptiometry (DXA) 
and fall risk assessment (26). 
In 2012, clinical guidelines for LOPD published by 
the Spanish Society of Internal Medicine, Spanish Soci-
ety of Neurology, and the Spanish Society of Pneumol-
ogy and Thoracic Surgery, concluded that nutritional 
intervention and aerobic exercise can improve motor 
function in patients with LOPD, albeit with a low level 
of evidence (29).
More recently, the 2016 Brazilian guidelines for the 
diagnosis, treatment and clinical monitoring of patients 
with juvenile and adult Pompe disease were based on the 
ICF criteria (30). Recommendations for the management 
of the musculoskeletal impairments in Pompe disease, in-
cluded: enrolling the patient in the International Pompe 
Registry; physical examination; physical/occupational 
therapy; management of contractures; vitamins and min-
erals supplementation (30).
Other groups have addressed the issue of motor reha-
bilitation in LOPD. The 208th European Neuromuscular 
Centre international workshop agreed on a minimal data-
set of outcome measures for adult patients with Pompe 
disease  (31). These included; muscle strength (manual 
muscle testing using the Medical Research Council grad-
ing scale, hand-held dynamometry, quantitative muscle 
testing), muscle function (6MWT, four timed tests in-
cluding walking 10 meters, climbing four steps, stand-
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ing up from the supine position, and standing up from a 
chair), pulmonary function (forced vital capacity [FVC] 
standing and sitting, maximal inspiratory pressure [MIP], 
maximal expiratory pressure [MEP], ventilation status), 
patient reported outcomes (Rasch-built Pompe-specific 
activity scale, fatigue severity scale), and other informa-
tion (treatment and survival status) (31). It was envisaged 
that the minimal dataset will allow for data sharing pur-
poses in order to address specific research questions.
Evidence-based guidelines on the diagnosis and 
management of Pompe disease from a Canadian expert 
panel identified seven management guidelines and made 
six recommendations (based on best clinical practices but 
with insufficient data to draw guidelines)  (32). Recom-
mendations related to the assessment of musculoskeletal 
impairments and rehabilitation included the following 
two statements: “Patients with LOPD should be encour-
aged to perform both resistance and cardiovascular ex-
ercise to improve general conditioning and quality of 
life. Interventions should be tailored to individual abili-
ties” and, “Periodic quality of life assessments and/or 
motor function tests, which can include questionnaires, 
should be part of the routine management of patients with 
LOPD” (32).
Rehabilitation of respiratory 
function in LOPD: state of the art 
In LOPD, morbidity and mortality due to progres-
sive respiratory muscle weakness are a major concern 
and management of respiratory function should include 
a multidisciplinary approach of neurologists, pulmonolo-
gists, and intensive care specialists (1). Clinical presenta-
tion of respiratory muscle function impairments in LOPD 
patients includes restrictive ventilation (hypo-expanding 
thorax), ineffective cough, alteration of blood gases (from 
hypoventilation), impaired respiratory muscle strength, 
alteration of the respiratory pattern (relationship between 
respiratory rate and current volume), alteration of sleep 
pattern, and dyspnea in ADL.
The choice of the outcome measure 
International guidelines for the management of res-
piratory function in LOPD patients are well-grounded 
and defined, and indicate, among other recommendations, 
essential respiratory function tests to be performed from 
the onset of the disease to advanced phases (1), includ-
ing: pulmonary function tests, peak cough flow (PCF), 
strength of the respiratory muscles, competence of the 
glottis in the cough, measurement of oxygen saturation 
(SaO
2






These evaluations must be performed initially and re-
peated over time. Other aspects to be investigated concern 
stress tolerance, including: incremental tests (with evalu-
ation of desaturation and level of dyspnea); endurance 
tests (on a treadmill, with evaluation of desaturation and 
level of dyspnea); study of sleep quality (through stand-
ardized scales); 6MWT (with evaluation of desaturation 
and level of dyspnea); and, evaluation of ADL (from the 
point of view of both motor and respiratory function).
The pulsed arterial saturation and day time are im-
portant to diagnose the development of respiratory failure 
and to define the timing of the initiation of mechanical 
ventilation  (33). Furthermore, the measurement of oxy-
hemoglobin saturation is a useful and non-invasive ele-
ment for monitoring the presence of catarrhal space over 
time (1).
It is crucial that respiratory function is measured over 
time since the evolution of respiratory symptoms is high-
ly variable, as demonstrated by a study of 16 untreated 
patients with LOPD in which only one third of patients 
presented a rapid respiratory decline over a mean follow-
up of 16 years (34). Depending on the rate of disease pro-
gression, the authors recommended regular monitoring 
of LOPD patients every 6-12 months. Consequently, the 
need to repeat tests of respiratory function over time is 
extremely variable between patients, which contribute to 
the heterogeneity of existing approaches in the manage-
ment of Pompe disease, as confirmed by the results of two 
surveys recently conducted in Italy (35, 36).
The choice of the protocol
Patients should undergo regular evaluation by a 
pulmonologist who should initiate respiratory aids as 
needed so that potentially catastrophic situations dur-
ing acute chest colds can be avoided  (37, 38). Indeed, 
early diagnosis, aggressive treatment and close follow-
up after an acute event are imperative to avoid further 
deterioration towards acute respiratory failure and hos-
pitalization (1).
Dedicated approaches to pulmonologists’ interven-
tion in the management of LOPD have been published 
by Italian researchers (37). The cornerstones of the res-
piratory rehabilitative intervention are represented by the 
treatment of nocturnal hypoventilation and the manage-
ment of secretions  (39). Bronchial disruption must be 
suggested for preventive purposes and becomes impera-
tive in cases where there is a catarrhal obstruction, which 
can be detected by auscultation and by clinical signs and 
symptoms. The main objectives of this therapy are to 
promote airway clearance, the prevention and treatment 
of respiratory atelectasis and infections, and the mainte-
nance of a normal ventilation/perfusion ratio. These pe-
ripheral disruption interventions act with the purpose of 
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increasing the air flow at the peripheral level and with it 
promote the recovery of secretions in the upper airways 
(“Flutter” PEP Mask, autogenous drainage, ELTGOL 
[total slow expiration, performed at glottis open and in 
lateral decubitus]).
Cough assistance becomes necessary when PCF val-
ues below 270 L/min are reached, and techniques used 
include manually assisted coughing, air stacking, insuf-
flation/exsufflation, and high frequency chest wall oscil-
lation  (1). Selective assistance to the inspiratory phase 
can be obtained by means of hyperinsufflation (air stack-
ing with fan or an Ambu flask), selective expiratory as-
sistance by manual compression of the rib cage and abdo-
men (abdominal thrust), and global cough assistance with 
air-stacking plus abdominal thrust or a specific instru-
ment called an in-exsufflator, which acts by delivering, in 
rapid succession, a positive pressure of insufflation and a 
negative expiratory pressure.
Mechanical ventilation is achieved using either non-
invasive ventilation (NIV) or invasive ventilation. The 
indications of the guidelines for NIV are less conserva-
tive than in the past, with the intent of recruiting patients 
earlier to encourage gradual adaptation to these proce-
dures  (1). Patients who develop hypercapnic acute res-
piratory failure should be referred to a specialized center 
for assessment of long term mechanical ventilation. NIV 
increases survival, prevents nocturnal hypoventilation, 
improves nighttime saturation, sleep-related respiratory 
disorders, and gas exchange, improves QoL, avoids or 
postpones tracheotomy, and relieves symptoms (40, 41).
Home mechanical ventilation is to be consid-
ered when the patient has daytime hypercapnia (pa-
CO
2
 > 45 mmHg) or orthopnea or symptoms of nocturnal 
hypoventilation (morning headache, daytime hypersom-
nolence, disturbed sleep with frequent awakenings) in as-
sociation with at least one of the following symptoms: 
vital capacity < 50% of theoretical, MIP/MEP < 60% of 
theoretical, nocturnal oxygen desaturation (SaO
2
 < 88% 
for more than 5 consecutive minutes), and close exacer-
bations (1). 
Published evidence supports the effectiveness of res-
piratory muscle training in increasing MIP  (42, 43) and 
improving the strength of both inspiratory and expiratory 
muscles (the latter being important for the cough function) 
(44). Inspiratory muscle training for 8-weeks was shown 
to have a significant (p  =  0.01 vs baseline) positive ef-
fect on MIP in 8 patients with LOPD who were receiving 
ERT (42). This finding was confirmed in 8 patients with 
LOPD treated with ERT who completed 24 months of res-
piratory muscle training and showed significant increases 
in MIP over a period of 24 months (p < 0.05 at 3, 6, 9, 12, 
and 24 months vs baseline) (43). Evaluation of MEP over 
the 24-month treatment period also demonstrated signifi-
cant increases in MEP from baseline at 3, 6, and 9 months 
Table 3. Essential respiratory function tests for the management of respiratory function in patients with late-onset 
Pompe disease.
Respiratory function test Description
Pulmonary function tests Slow vital capacity and FVC both in a sitting and supine position where a restrictive ven-
tilator pattern is usually diagnosed [vital capacity values < 50% predicted (49)] or inspir-
atory vital capacity values [ < 60% predictive of sleep-disordered breathing and < 40% 
predictive of sleep-related hypoventilation (50, 51)] (1)
Peak cough flow Measurement of air flow generated during the cough evaluates the effectiveness of the 
mechanism of cough [a value < 160 L/min reflects inadequate airway clearance (48)]
Strength of the respiratory 
muscles
MIP, MEP, and sniff nasal inspiratory pressure are indicators of diaphragm weakness 
and are therefore indications for NIV or poor ability to generate cough (1)
Competence of the glottis 
in the cough
Calculated using the passive maximum intake inspiratory capacity, which is the maxi-
mum capacity of the lung to be passively inflated through air boluses delivered by a fan 
or an Ambu flask (1)
Measurement of SaO2 at 
night
Measurement of SaO2 at night using cardiorespiratory monitoring or polysomnography. 
Sleep studies are useful to monitor nocturnal hypoventilation (and therefore the need for 
NIV) by measurement of nocturnal oximetry, use of a CO2 transdermal tension meter as 
well as a complete sleep study using polysomnography (1)
Blood gas analysis Measurement of oxygen and carbon dioxide levels in an arterial blood sample to monitor 
the adequacy of oxygenation and ventilation. This is the ‘gold standard’ for the assess-
ment of hypoventilation
Transcutaneous monitoring 
of paO2 and paCO2
Provides information on both the CO2 status and O2 delivery to the tissues
Abbreviations: FVC, forced vital capacity; MEP, maximal expiratory pressure; MIP, maximal inspiratory pressure; NIV, non-invasive 
ventilation; paCO2, partial pressure of carbon dioxide; paO2, partial pressure of oxygen; SaO2, oxygen saturation.
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(all p < 0.05) but not at 12 and 24 months; FVC remained 
stable throughout the study period (43). In addition, Jones 
et al. showed improved inspiratory and expiratory muscle 
strength in 8 adults with LOPD receiving ERT follow-
ing a 12-week respiratory muscle training program, with 
positive changes largely persistent after 3-months detrain-
ing  (44). The authors concluded that respiratory muscle 
training offers a potential adjunctive treatment for respira-
tory weakness in patients with LOPD.
However, a survey on attitudes and practices in It-
aly for the management of NMD found that rehabilita-
tive approaches used in clinical practice include mainly 
mechanical ventilation (96.5%) and bronchial disruption 
(84.2%), while respiratory muscle training was used in 
only 36.6% of cases (36). 
Ambrosino and colleagues divided the possible 
outcome measures for patients with LOPD into three 
groups based on the level of progression and disease 
severity (Table 4) (37). This is a clinical-functional clas-
sification, and it would be of interest to link with the ICF 
criteria. Studies on the use of ERT in LOPD use FVC, 
MEP and MIP as the main outcome measures (6, 7, 10, 
11, 45, 46), however these endpoints are characterized 
by high variability, which reduces the reliability of such 
spirometric data. An alternative endpoint can be repre-
sented by the number of hours of mechanical ventilation 
required (47).
Lastly, considerations on the palliative setting should 
be performed, which are in line with position papers re-
ferring to the Italian setting (35, 39). For end-stage LOPD 
patients, the wishes of the patient should be respected, 
decisions must be based on a shared process, and medical 
treatment must be proportionate; if the patient chooses 
to not use mechanical ventilation, they must receive ad-
equate palliative care. 
Unmet needs in the rehabilitation 
of LOPD patients and future 
perspectives
On the bases of the criticisms discussed in the first pa-
per produced by this multidisciplinary group, a number of 
unmet needs have been identified in the rehabilitation of 
motor and respiratory function of LOPD patients (Table 5). 
The next step of the working group will be to inves-
tigate which functioning categories, according to the ICF, 
are most impaired in patients with LOPD, and to propose a 
practical approach to address specific management strate-
gies, including physical activity, therapeutic exercise pro-
grams for global and specific motor function impairments, 
patients’ education for healthy lifestyle, enhancement 
strategies to improve social participation, and QoL. 
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